Gilead Sciences, a biopharmaceutical company, agreed to invest $320m in Arcus Biosciences, a biopharmaceutical company. “This amendment allows Gilead to accelerate the domvanalimab program and enables Arcus to focus on progressing multiple pipeline assets, including both Gilead-optioned and non-optioned programs. We look forward to strengthening our collaboration as we explore the collective power of our cross-portfolio combinations to help transform how cancer is treated,” Merdad Parsey, Gilead Sciences Chief Medical Officer.